Multiple clinical trials have shown that HER2-targeted treatment with monoclonal antibodies such as TZB in patients with HER2+ breast cancer have advanced survival outlook, especially considering that these patients started with a very poor prognosis. Here, ERBB2 is linked to breast cancer.